CEACAM6 and neoplasm: A decrease in SFTPA1 expression (an AT2 marker) was observed, whereas CEACAM6 and SPINK1 (CAS markers) exhibited high expression levels in tumour regions (GG and S) compared to the DN region (Figure 2E).